---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017313"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:51:47.014851+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Virios provides pipeline update: IMC-1 Phase 3 partnership discussions, IMC-2 FDA briefing for Long-COVID

## Summary
- FDA guidance received for IMC-1 Phase 3 fibromyalgia trial; multiple life science companies reviewing Phase 2 data for partnership.
- Briefing materials submitted to FDA for IMC-2 Investigational New Drug application to treat Long-COVID (no approved LC treatments yet).
- Filed provisional method-of-use patents for IMC-2 in Long-COVID and Alzheimer's disease, covering through at least 2043.
- Cash runway expected to support operations into Q3 2024 due to expense management.

## SEC filing metadata
- accession: 0001558370-23-017313
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023017313/0001558370-23-017313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023017313/tmb-20231102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017313
- JSON: https://secwatch.observer/filing/0001558370-23-017313.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.